Journal of Thyroid Cancer · About JTC
About the Journal of Thyroid Cancer
Journal of Thyroid Cancer (JTC) is a peer-reviewed, open-access journal published by Open Access Pub. It applies one editorial standard to laboratory, diagnostic, operative, therapeutic and population evidence about a single disease: thyroid carcinoma.
01 · Identity
A journal for one disease
JTC is a specialist journal in thyroid oncology. Its subject is thyroid carcinoma in all its forms — papillary and follicular carcinoma and the differentiated disease they comprise, medullary carcinoma, poorly differentiated and anaplastic carcinoma, and the rare malignancies that arise in or metastasize to the thyroid. It publishes mechanistic, translational and clinical research across the biology of these tumors, their cytologic and molecular diagnosis, imaging, surgery, radioiodine and systemic therapy, and the long-term outcomes of treatment.
It is not a general endocrinology journal and not a general oncology journal. Benign thyroid disease enters its pages where it bears on cancer — the indeterminate nodule, differential diagnosis, tumor classification, molecular risk assessment and the surgical decision that follows — rather than as a subject in its own right.
02 · Purpose
A single record for a divided subject
Thyroid oncology draws on laboratory biology, cytopathology, imaging, surgery, nuclear medicine, endocrinology, medical oncology, and population research. JTC brings these contributions into one scholarly record while assessing each study according to its research question and design.
JTC exists to hold those readings in one place. A surgical series and a study of BRAF-driven signaling are not competing subjects here; they are two accounts of the same tumor, and the journal is edited on the premise that each is more useful when the other is nearby. That is the practical case for a single-disease title: the evidence a clinician needs in order to act is distributed across disciplines that read different journals.
The journal focuses on thyroid oncology. It does not attempt to cover endocrine neoplasia generally, and it does not publish work whose relevance to thyroid carcinoma has to be inferred. What it offers an author is a readership that already works on this disease.
03 · Multidisciplinary practice
How the disciplines converge
Thyroid-cancer care is a sequence, and each discipline hands the patient to the next. The journal is organized around that sequence rather than around specialty boundaries, and a manuscript is read by editors who work at the point in it that the manuscript addresses.
The course the journal reads across
- Biology
- Diagnosis
- Treatment
- Outcomes
-
Molecular biology and genetics
Establishes what drives the tumor — BRAF, RAS and RET alterations, the signaling they dysregulate, and the hereditary syndromes behind medullary disease. It defines the categories every later discipline uses.
-
Cytopathology and pathology
Turns an aspirate or a specimen into a diagnosis and a classification. It is where the benign and malignant boundary is actually drawn, and where indeterminate results become a clinical problem for everyone downstream.
-
Radiology and ultrasound
Characterizes the nodule, stages the neck, guides the needle, and increasingly treats the lesion directly through ablative and image-guided technique.
-
Endocrine surgery
Decides extent of thyroidectomy and lymph-node management on evidence generated by the three disciplines above, and generates the operative and complication data the rest of the field relies on.
-
Nuclear medicine
Selects and doses radioiodine, images the result, manages radiation safety, and identifies the point at which disease has become refractory.
-
Medical oncology and endocrinology
Takes over when radioiodine stops working, selects kinase- and RET-directed therapy on molecular evidence, and carries the long follow-up — thyroglobulin surveillance, response reassessment, and the endocrine and quality-of-life consequences patients live with for decades.
04 · Readership
Who the journal is for
JTC is written for the clinicians and scientists who manage and study thyroid carcinoma, and for the trainees entering those fields. It assumes working knowledge of the disease and does not simplify for a general audience.
- Endocrinologists
- Endocrine and head-and-neck surgeons
- Medical oncologists
- Nuclear-medicine physicians
- Pathologists and cytopathologists
- Radiologists and interventional radiologists
- Molecular and translational researchers
- Clinical, outcomes and survivorship researchers
- Epidemiologists and health-services researchers
05 · Research integrity
Clinical research about identifiable people
Most of what JTC publishes concerns patients. The obligations that follow from that are treated as conditions of publication rather than as aspirations, and they apply equally to a single case report and to a multicenter cohort.
-
Ethics approval and consent
Research involving people, human material or identifiable data reports the approving ethics committee or institutional review board and the consent obtained. Case reports and clinical images require documented consent to publish.
-
Patient privacy
Identifying details are removed from text, tables, images and supplementary files unless they are essential to the science and the patient has consented to their publication.
-
Trial registration
Interventional clinical trials must be registered in an accepted public trial registry at or before the first participant provides consent for enrollment. The registry name, registration number, and registration date must be reported in the manuscript.
-
Claims held to the design
Staging and classification systems, cohort definitions and statistical methods are reported in full, and conclusions are held to what the design supports: a retrospective or observational study describes association, not causation, and a biomarker association is not a validated clinical test.
-
Data availability
Every empirical research manuscript must include a data-availability statement.
-
Funding and competing interests
Funding sources, grant numbers and competing interests are declared by every author, and editors and reviewers withdraw from any manuscript in which they have an interest.
06 · Publishing principles
How the journal is published
Peer review
All submissions undergo initial editorial screening. Manuscripts that meet the journal's scope and minimum requirements proceed to independent peer review. Single-blind by default; double-blind review is available on request. Manuscripts that proceed to external peer review are normally evaluated by at least two independent subject-matter experts.
Editorial independence
Editorial decisions are based on scope, scientific quality, methodological rigor, ethical compliance, reporting quality, and relevance to the journal. Reviewers advise; the decision is the editor's, and it is taken independently of any fee, membership, service or role.
Open access and rights
Every article is open access from publication under the Creative Commons Attribution 4.0 International license, with copyright retained by the authors. There is no reader charge and no subscription.
The citable record
JTC uses Crossref DOI registration and article metadata deposits under the prefix 10.14302. Article metadata is exposed for harvesting by libraries and aggregators.
Corrections and retractions
Corrections, expressions of concern and retractions follow COPE guidance, are linked to the article they concern, and remain part of the permanent record rather than replacing it.
Long-term availability
The journal participates in Open Access Pub's digital-preservation program, so the record remains available independently of the publisher's own platform.
07 · Editorial responsibility
Who is accountable
Editorial responsibility rests with the Editor-in-Chief, Giovanni Mauri, Associate Professor at the Università degli Studi di Milano, Italy (ORCID 0000-0003-4726-2692), supported by an editorial board whose members work in the disciplines the journal covers: endocrinology, endocrine surgery, nuclear medicine, interventional radiology, cytopathology, molecular oncology and cancer epidemiology.
Handling editors are assigned by subject rather than by rota, and an editor who has an interest in a manuscript — institutional, financial or personal — takes no part in its assessment. Editors who publish in the journal are handled by another editor, and their authorship is disclosed on the published article.
- Editorial board
- 15 members
- Countries represented
- 11
- Members with an ORCID iD
- 10
08 · Journal facts
The record at a glance
- Full title
- Journal of Thyroid Cancer
- Abbreviation
- JTC
- ISSN (electronic)
- 2574-4496
- Publisher
- Open Access Pub
- Access model
- Open access, no reader charge
- License
- CC BY 4.0; authors retain copyright
- DOI registration
- Crossref, prefix 10.14302
- Peer review
- Single-blind by default; double-blind on request
- Article types
- Research articles, reviews, methods papers, short communications, case reports and series, editorials and commentaries
- Published record
- 13 published records
- Volume and issues
- Volume 1, Issues 1–4
- Publication history
- 2015–2026
Archive totals reflect the journal's current published record. Publication is funded by an article processing charge, raised only after a manuscript has been accepted; there is no submission fee. The charge by article type is set out on the article processing charges page.
Where to go next
Read on
If this page answered the question you arrived with, these answer the next one.
Journal of Thyroid Cancer (JTC) · ISSN 2574-4496 · Crossref DOI prefix 10.14302 · published open access by Open Access Pub under CC BY 4.0, with copyright retained by authors. Editorial decisions are independent of any fee, service, membership or role.